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Stereotactic body radiotherapy (SBRT) or stereotactic ablative radiotherapy is increas-ingly used to treat early-stage non–small-cell lung cancer. In large series, at 5 years, 
control rates for the primary tumor were reported to be approximately 90%, regional con-
trol about 85%, whereas distant recurrences were observed in 20% of patients.1 These 
results have been confirmed in many, including multicenter, reports.2 Toxicity is mostly 
mild with less than 10% grade 3 adverse events. The patterns of failure after SBRT have 
been reported to be similar to those after lobectomy or pneumonectomy.3
Although randomized trials have not been reported, on comparison of prospective 
series, SBRT showed similar cancer control than sublobar resection but with a favorable 
toxicity.4 Long-term results with radiofrequency ablation are lacking.4 Whereas in early 
series the vast majority of patients had significant comorbidities, more recently borderline 
or undoubtedly operable patients also have been successfully treated with SBRT.5
It is clear that improving these outcomes will be challenging and will require the 
identification of patients at high risk for recurrence to select them for clinical trials. Ideally, 
prognostic factors that identify individuals at risk for either local, regional, or distant 
relapses would be needed.
Increasing local tumor control simply by escalation of the radiotherapy dose is unlikely 
to affect the outcome.6 Indeed, the radiation doses that are delivered to typical small coin 
lesions such as three fractions of 18 Gy already exceed the levels required to kill all cancer 
cells. Data from a meta-analysis suggest that these high doses may even be an overkill for 
many patients with tumors up to 3 cm in diameter.6 If SBRT is delivered with appropriate 
techniques,7 including motion management, it is more likely that individualizing the margins 
of microscopic extensions (the clinical target volume [CTV]) around the visible tumor (the 
gross tumour volume) may result in even lower local recurrences than observed in recent 
series. Computed tomography or 18F-deoxyglucose (FDG)-positron emission tomography 
(PET) image features can predict the CTV.8,9 These studies show that a significant proportion 
of tumors may have been irradiated with too small volumes and that incorporating these novel 
image features in the CTV definition may decrease failures resulting from geographical miss.9
The results reported by Takeda and colleagues10 in this issue give insight on how 
FDG-PET-computed tomography data may be the basis for outcome improvement. In this 
retrospective series in 152 patients with early non–small-cell lung cancer treated with 
SBRT, the maximal standardized uptake value was a predictor for outcome. This included 
local control, regional recurrence, and distant metastases. Obviously, the maximal stan-
dardized uptake value thresholds that were identified in this retrospective series are not for 
standard clinical use and it may even be questioned whether this parameter will turn out to 
be the most optimal. Moreover, some patients definitely had noninvasive adenocarcinoma 
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in situ, a disease that is associated with a better outcome and 
low FDG avidity.
Nevertheless, this study adds to the existing literature11 
that on the basis of FDG-PET patients who need a more inten-
sive treatment than current SBRT may be selected. As already 
mentioned, this may include other CTV margins, adjuvant 
irradiation on hilar and mediastinal lymph node regions, and 
adjuvant chemotherapy in fit patients.
The time has come to move to randomized trials address-
ing these questions. This will ultimately result in a more tai-
lored approach with even better outcome with SBRT.
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